Skip to content

Biolivon publishes the science.

Biolivon
Longevity Science

Aging biology, minus the wishful thinking

Longevity is the field with the widest gap between what is marketed and what is known. We report the biology honestly, including how much of it remains unresolved.

Explore the biologyBiomarker library
  • Outcome data over surrogate markers
  • Animal results not extrapolated
No compound has been shown to extend human lifespan. That sentence is the honest state of the field as of today, and any page that implies otherwise is selling something. Interesting biology is worth following — it is not yet worth acting on.

Four things to hold onto

The framing that makes the rest legible

The interventions with the best evidence are unglamorous

Resistance training, cardiorespiratory fitness, sleep, not smoking, and managing blood pressure and lipids have decades of human outcome data behind them. No peptide currently comes close to that evidence base.

Biological age tests are not outcomes

Epigenetic clocks and similar measures are research tools with meaningful measurement variability. A test moving is not the same as your health improving, and no clock has been validated as a target to treat.

Animal lifespan results rarely transfer

Interventions that extend lifespan in short-lived species have a poor track record in humans. Species differences in metabolism and cause of death are the reason, not insufficient dosing.

Surrogate markers are not the goal

A compound can improve a biomarker and change nothing about how long or how well you live. Outcome data is scarce in this field precisely because it takes decades to produce.

Areas

Explore the biology

Healthy Aging

Biological aging, senescence, and what ageing biomarkers can and cannot show.

Mitochondrial Health

Energy production, mitochondrial stress signalling and cardiolipin biology.

Metabolic Health

Glucose regulation, incretin biology, weight and cardiometabolic risk.

Brain and Cognition

Neuroplasticity, cognition research, and the limits of nootropic claims.

Muscle and Recovery

Tissue repair, tendon and muscle biology, and recovery research.

Sleep and Circadian Biology

Sleep architecture, circadian timing and the peptides studied around them.

Dossiers

Compounds studied in this space

Note how many sit at Preclinical or Insufficient. That distribution is the honest picture of the field.

5-Amino-1MQ

Preclinical

A small-molecule NNMT inhibitor studied in mouse models of obesity.

0 human studies · 1 preclinical

AOD-9604

Tested, no benefit

A growth-hormone fragment developed for obesity, on the premise of fat loss without growth effects.

0 human studies · 0 preclinical

BPC-157

Preclinical

Tissue-repair signalling in tendon, muscle and gastrointestinal models.

0 human studies · 2 preclinical

Cagrilintide

Promising

Long-acting amylin analogue studied for weight management, principally in combination with semaglutide.

1 human study · 0 preclinical

Cardiogen

Insufficient

A short peptide from the Khavinson bioregulator tradition, associated with cardiac tissue.

0 human studies · 1 preclinical

Cartalax

Insufficient

A short peptide from the Khavinson bioregulator tradition, associated with cartilage and connective tissue.

0 human studies · 1 preclinical

CJC-1295

Preliminary

GHRH analogue studied for sustained elevation of growth hormone and IGF-1.

1 human study · 0 preclinical

DSIP

Insufficient

A nonapeptide identified in sleep research, studied for sleep and stress responses.

1 human study · 0 preclinical

Elamipretide (SS-31)

Preliminary

Cardiolipin-targeted mitochondrial protection in primary mitochondrial disease and cardiomyopathy.

1 human study · 0 preclinical

Eloralintide

Preliminary

A long-acting amylin receptor agonist in clinical development for obesity.

1 human study · 0 preclinical

Epitalon

Insufficient

A short peptide from the Khavinson bioregulator tradition, studied in pineal regulation and ageing.

1 human study · 0 preclinical

GHRP-2

Insufficient

Non-selective growth-hormone secretagogue. Its best-evidenced human uses are diagnostic testing of pituitary reserve and, separately, stimulation of appetite.

5 human studies · 0 preclinical

GHRP-6

Preliminary

Early non-selective growth-hormone secretagogue, used in humans mainly as a pituitary provocation agent for diagnostic testing rather than as a treatment.

1 human study · 0 preclinical

Glutathione

Safety concern

The body's principal intracellular antioxidant tripeptide, sold for injection and infusion.

1 human study · 0 preclinical

Hexarelin

Preliminary

Potent growth-hormone secretagogue, also studied for cardiac effects independent of growth hormone.

1 human study · 1 preclinical

HGH 191AA

Tested, no benefit

Recombinant human growth hormone — an approved medicine, sold in this category for uses it was tested for and failed.

1 human study · 0 preclinical

IGF-1 LR3

Safety concern

A cell-culture reagent version of IGF-1, engineered to evade binding proteins.

0 human studies · 2 preclinical

Ipamorelin

Preliminary

Selective ghrelin receptor agonism for growth-hormone release without the cortisol and prolactin rise of older secretagogues.

1 human study · 1 preclinical

KLOW

Insufficient

A multi-compound blend combining several research peptides in one vial.

0 human studies · 0 preclinical

MK-677

Tested, no benefit

Orally active non-peptide growth-hormone secretagogue studied in sarcopenia, frailty and hip fracture recovery.

2 human studies · 0 preclinical

MOTS-c

Preclinical

Mitochondrial-derived peptide signalling in metabolic regulation and exercise physiology.

1 human study · 1 preclinical

N-Acetyl Selank

Insufficient

An acetylated variant of Selank sold on the research market.

0 human studies · 0 preclinical

N-Acetyl Semax

Insufficient

An acetylated variant of Semax sold on the research market.

0 human studies · 1 preclinical

NAD+

Insufficient

A coenzyme central to cellular energy metabolism, sold injectably and as oral precursors.

1 human study · 0 preclinical

Pinealon

Insufficient

A short peptide from the Khavinson bioregulator tradition, associated with brain tissue.

1 human study · 1 preclinical

Retatrutide

Promising

Triple GIP, GLP-1 and glucagon receptor agonism in obesity and metabolic disease.

1 human study · 0 preclinical

Selank

Preliminary

A tuftsin analogue used clinically in Russia for anxiety disorders.

1 human study · 0 preclinical

Semaglutide

Established

GLP-1 receptor agonism in type 2 diabetes, weight management and cardiovascular risk.

2 human studies · 0 preclinical

Semax

Preliminary

A melanocortin fragment analogue used clinically in Russia for cerebrovascular and cognitive indications.

1 human study · 0 preclinical

SLU-PP-332

Preclinical

A small-molecule ERR agonist described as an exercise mimetic.

0 human studies · 1 preclinical

TB-500

Preclinical

Actin-sequestering peptide fragment studied in wound healing and tissue repair models.

0 human studies · 2 preclinical

Tesamorelin

Established

GHRH analogue studied for visceral adipose reduction in HIV-associated lipodystrophy.

2 human studies · 0 preclinical

Testagen

Insufficient

A short peptide from the Khavinson bioregulator tradition, associated with testicular tissue.

0 human studies · 1 preclinical

Tirzepatide

Established

Dual GIP and GLP-1 receptor agonism in type 2 diabetes and obesity.

1 human study · 0 preclinical

Vesugen

Insufficient

A short peptide from the Khavinson bioregulator tradition, associated with vascular tissue.

1 human study · 1 preclinical